Morgan Stanley Upgrades Johnson & Johnson to Overweight, Increases PT to $262
Terence Flynn from Morgan Stanley remains bullish on the company as he expects higher estimates from Johnson & Johnson’s new products.
Johnson & Johnson (JNJ)
Market is closed
Sector: Pharmaceutical Preparations
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period: Filing is Ongoing
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Levin Capital Strategies John A. Levin | 207,100 | $42,859,345 | -1% | 3.7% |
| 2. | Impax Asset Management Ian Simm | 108,397 | $22,432,759 | -11% | 0.14% |
| 3. | Beech Hill Partners Paul Cantor, Joseph Weiss, And Will Wurm | 13,949 | $2,886,720 | -4% | 1.38% |
| 4. | Zevenbergen Capital Investments Nancy Zevenbergen | 10,964 | $2,269,000 | +2% | 0.05% |
| 5. | Bourgeon Capital John Zaro | 10,134 | $2,097,232 | +98% | 0.34% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $206.15 | 1,250 | $257,687.50 | 1,849 | 2025-11-26 | Filing | |
| $145.53 | 100 | $14,553.00 | 250 | 2024-04-30 | Filing | |
| $147.22 | 1,000 | $147,220.00 | 1,000 | 2024-12-12 | Filing | |
| $127.69 | 500 | $63,843.00 | 16,030 | 2020-03-13 | Filing | |
| $141.28 | 5,000 | $706,399.00 | 5,000 | 2019-12-13 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $221.48 | 48,782 | $10,804,432.49 | 30,852 | 2026-01-26 | Filing | |
| $220.99 | 51,218 | $11,318,460.95 | 79,634 | 2026-01-26 | Filing | |
| $192.71 | 21,721 | $4,185,793.09 | 10,658 | 2025-10-17 | Filing | |
| $177.81 | 56,471 | $10,040,882.63 | 178,013 | 2025-09-04 | Filing | |
| $179.21 | 125,824 | $22,548,654.81 | 275,967 | 2025-08-22 | Filing |
Institutional Investors' Holdings
Filing Period: Filing is Ongoing
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 240,349,660 | $49,740,362,171 | 0.72% | |
| 2. | 16,388,566 | $3,391,613,735 | 1.09% | |
| 3. | 9,984,291 | $2,066,249,024 | 0.34% | |
| 4. | 6,810,748 | $1,409,484,211 | 3.02% | |
| 5. | 5,946,335 | $1,230,594,028 | 0.72% |
News See All
10 Hottest Stocks to Buy in 2026
After reaching a record high on January 27, the S&P 500 index fell for three consecutive sessions, closing at 6,939.03 on Friday.
15 Best Long Term Low Volatility Stocks to Invest In
According to her, one of the most important things that came out of Davos was going from the phrase globalization to the “new world order”, in which the former felt more like a conscious uncoupling...
Is Johnson & Johnson (JNJ) The Most Profitable Healthcare Stock To Buy?
Johnson & Johnson (NYSE:JNJ) is among the most profitable healthcare stocks to buy.
10 Most Profitable Healthcare Stocks to Buy
By far, the healthcare sector remains among the most resilient and profitable in global equity markets.
Scotiabank Raises Johnson & Johnson (JNJ) Target on Strong Quarterly Results
The bigger takeaway was how well J&J seems to be managing its patent pressures. Stelara is already dealing with biosimilar competition, and more challenges are lined up.
12 Best Dow Jones Dividend Stocks to Buy According to Hedge Funds
The Dow Jones Industrial Average tracks 30 large, well-established companies across areas like finance, technology, and pharmaceuticals.
Guggenheim Lifts Johnson & Johnson (JNJ) Outlook After Solid Q4 and 2026 Guide
On January 23, Guggenheim analyst Vamil Divan raised his price target on Johnson & Johnson (NYSE:JNJ) to $240 from $227. The firm reiterated a Buy rating.
JNJ Delivers Strong 2026 Guidance Even as Policy Costs Loom
Johnson & Johnson (NYSE:JNJ) posted its fourth-quarter 2025 earnings on January 21 and followed it up with a 2026 outlook that came in ahead of Wall Street expectations.
15 Best S&P 500 Dividend Stocks to Buy in 2026
Dividend stocks have often provided stability when markets get difficult.
Hedge Fund Resource Center Billionaire Hedge Funds
